Patiromer
- Generic Name
- Patiromer
- Brand Names
- Veltassa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1260643-52-4
- Unique Ingredient Identifier
- 1FQ2RY5YHH
- Background
Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2...
- Indication
Patiromer is indicated for the treatment of hyperkalemia.
- Associated Conditions
- Hyperkalemia
- Associated Therapies
- -
Patiromer With or Without Food for the Treatment of Hyperkalemia
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT02694744
- Locations
- 🇺🇸
Investigator Site 12, Fountain Valley, California, United States
🇺🇸Investigator Site 20, Riverside, California, United States
🇺🇸Investigator Site 10, Hialeah, Florida, United States
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02033317
- Locations
- 🇺🇸
Investigator Site, Minneapolis, Minnesota, United States
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
- Conditions
- Interventions
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT01810939
- Locations
- ðŸ‡ðŸ‡·
Investigator Site 1105, Zagreb, Croatia
🇬🇪Investigator Site 1312, Tbilisi, Georgia
ðŸ‡ðŸ‡·Investigator Site 1106, Zagreb, Croatia
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
- Conditions
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT01371747
- Locations
- 🇬🇪
Investigator Site 311, Tbilisi, Georgia
🇬🇪Investigator Site 303, Tbilisi, Georgia
🇬🇪Investigator Site 308, Tbilisi, Georgia
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01130597
- Locations
- 🇬🇪
Investigator Site 11, Tbilisi, Georgia
🇬🇪Investigator Site 12, Tbilisi, Georgia
🇸🇮Investigator Site 22, Maribor, Slovenia
Evaluation of Patiromer in Heart Failure Patients
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00868439
- Locations
- 🇺🇸
Investigator Site 031, Port Charlotte, Florida, United States
🇺🇸Investigator Site 009, Peoria, Illinois, United States
🇺🇸Investigator Site 018, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.